
Julie Brahmer
Co-Director of the Upper Aerodigestive Department Within the Bloomberg~Kimmel Institute for Cancer Immunotherapy · Johns Hopkins University School of Medicine
Credentials: · · ·
History
- Present
Upper Aerodigestive Department within the Bloomberg~Kimmel Institute for Cancer Immunotherapy · Johns Hopkins University School of Medicine
- 1996–1998
Medical Oncology
- 1993–1996
Internal Medicine
- 1989–1993
Doctor of Medicine
Research
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
New England Journal of Medicine · 2012 · 10,404 citations
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2016 · 8,389 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · Last of 28 authors · 7,953 citations
- PF
78 papers
- JN
48 papers

48 papers · 5 as a fellow

41 papers · 2 as a fellow
- CH
33 papers · 1 as a fellow
- DE
29 papers
- JS
27 papers
- JF
27 papers
Grants
- 2019–2032
National Cancer Institute · UG1
Contact PI · $4.6M · Johns Hopkins University
- 2014–2019
Johns Hopkins University NCTN Lead Academic Site Program
National Cancer Institute · U10
Contact PI · $3.3M · Johns Hopkins University
- 1997–2017
Regional Oncology Research Center
National Cancer Institute · P30
Project lead · $423.9K · Johns Hopkins University
Clinical trials
- 2019–2028
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Principal investigator · Active not recruiting · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 2013–2023
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Principal investigator · Completed · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 2013–2017
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
- 2011–2015
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Principal investigator · Completed
Wake Forest University
